Acelarin (Synonyms: NUC-1031)

Name: Acelarin
Brand: MedChemExpress
SKU: HY-100885
Rating: 4.5 (1 reviews)

製品番号: HY-100885 純度: 99.13%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Acelarin 構造式

CAS 番号 : 840506-29-8

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 140	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 140	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$110	在庫あり	Estimated Time of Arrival: December 31
10 mg	$180	在庫あり	Estimated Time of Arrival: December 31
25 mg	$350	在庫あり	Estimated Time of Arrival: December 31
50 mg	$535	在庫あり	Estimated Time of Arrival: December 31
100 mg	$746	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Other Forms of Acelarin:

(S)-Acelarin お問い合わせ
(R)-Acelarin お問い合わせ

顧客検証

•Cancer Chemother Pharmacol. 2020 Jun;85(6):1063-1078. [Abstract]

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine.

IC₅₀ & Target

EC50：0.2 nM (DNA synthesis inhibitor)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.27 μM Compound: NUC1031	Cytotoxicity against human A2780 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human A2780 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
BXPC-3	IC₅₀	0.15 μM Compound: 6f, NUC-1031	Cytostatic activity against human BxPC3 cells after 72 hrs by MTS assay Cytostatic activity against human BxPC3 cells after 72 hrs by MTS assay	[PMID: 24471998]
BXPC-3	IC₅₀	0.33 μM Compound: NUC1031	Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
BXPC-3	IC₅₀	230.1 nM Compound: NUC-1031	Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay	[PMID: 36867101]
CCRF-CEM	IC₅₀	0.1 μM Compound: 6f, NUC-1031	Cytostatic activity against human CEM cells after 72 hrs by coulter counter analysis Cytostatic activity against human CEM cells after 72 hrs by coulter counter analysis	[PMID: 24471998]
COLO 205	IC₅₀	1.82 μM Compound: NUC1031	Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
CWR22R	IC₅₀	130.1 nM Compound: NUC-1031	Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay	[PMID: 36867101]
HEL	CC₅₀	0.34 μM Compound: 2c	Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis	[PMID: 33479570]
HepG2	IC₅₀	1.16 μM Compound: NUC1031	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
HT-29	IC₅₀	0.48 μM Compound: NUC1031	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
Huh-7	IC₅₀	350.3 nM Compound: NUC-1031	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay	[PMID: 36867101]
JeKo-1	IC₅₀	160.1 nM Compound: NUC-1031	Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay Antiproliferative activity against human JeKo-1 cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay	[PMID: 36867101]
L1210	IC₅₀	0.035 μM Compound: 6f, NUC-1031	Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counter analysis Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counter analysis	[PMID: 24471998]
MDA-MB-231	IC₅₀	1 μM Compound: NUC1031	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MIA PaCa-2	IC₅₀	0.12 μM Compound: NUC1031	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MIA PaCa-2	IC₅₀	0.44 μM Compound: 6f, NUC-1031	Cytostatic activity against human MIAPaCa2 cells after 72 hrs by MTS assay Cytostatic activity against human MIAPaCa2 cells after 72 hrs by MTS assay	[PMID: 24471998]
MIA PaCa-2	IC₅₀	142.2 nM Compound: NUC-1031	Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay	[PMID: 36867101]
MM1.S	IC₅₀	31.1 nM Compound: NUC-1031	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay	[PMID: 36867101]
MV4-11	IC₅₀	61 nM Compound: NUC-1031	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation treated for 72 hrs by resazurin dye-based fluorescence assay	[PMID: 36867101]
OVCAR-3	IC₅₀	119.05 μM Compound: NUC1031	Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
PANC-1	EC₅₀	162 μM Compound: 6f, NUC-1031	Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in presence of hENT1 inhibitor dipyridamole Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in presence of hENT1 inhibitor dipyridamole	[PMID: 24471998]
PANC-1	EC₅₀	190 μM Compound: 6f, NUC-1031	Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in absence of hENT1 inhibitor dipyridamole Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in absence of hENT1 inhibitor dipyridamole	[PMID: 24471998]
PANC-1	IC₅₀	3.96 μM Compound: NUC1031	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
PC-3	IC₅₀	1.09 μM Compound: NUC1031	Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
RT-112	EC₅₀	0.2 nM Compound: 6f, NUC-1031	Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in absence of dCK substrate deoxycytidine Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in absence of dCK substrate deoxycytidine	[PMID: 24471998]
RT-112	EC₅₀	0.7 nM Compound: 6f, NUC-1031	Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in presence of dCK substrate deoxycytidine Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in presence of dCK substrate deoxycytidine	[PMID: 24471998]
SK-MES-1	IC₅₀	0.11 μM Compound: NUC1031	Cytotoxicity against human SK-MES-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human SK-MES-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
Vero	CC₅₀	0.02 μM Compound: 2c	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis	[PMID: 33479570]

体外実験

Gemcitabine is a nucleoside analogue commonly used in cancer therapy but with limited efficacy due to a high susceptibility to cancer cell resistance. The addition of a phosphoramidate motif to the gemcitabine can protect it against many of the key cancer resistance mechanisms. A series of gemcitabine phosphoramidate prodrugs are synthesized and screened for cytostatic activity in a range of different tumor cell lines. Among the synthesized compounds, NUC-1031 is shown to be potent in vitro.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

The ProTide demonstrates a significant reduction in tumor size against pancreatic xenograft models compared with the gemcitabine treated group, and less adverse effects on body weight, indicating a better safety profile. Data strongly suggests that the ProTides are not reliant on kinases or nucleoside transporters to exert their activity inside tumor cells and remain stable in the presence of deaminases. The ProTide NUC-1031 is currently advancing through phase I/II clinical studies and has already generated strong pharmacokinetic data that confirm significantly higher intracellular levels of gemcitabine triphosphate, together with promising early efficacy signals and a favorable safety profile. The phosphoramidate chemistry is potentially a great source of new and very effective anticancer agents, bringing a considerable array of advanced treatments specifically designed to overcome cancer resistance mechanisms that will benefit a greater proportion of patients^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

分子量

580.47

分子式

C₂₅H₂₇F₂N₄O₈P

CAS 番号

840506-29-8

Appearance

Solid

Color

White to off-white

SMILES

O=C1N=C(N)C=CN1[C@@H]2O[C@H](COP(OC3=CC=CC=C3)(N[C@H](C(OCC4=CC=CC=C4)=O)C)=O)[C@@H](O)C2(F)F

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : ≥ 36 mg/mL (62.02 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7227 mL	8.6137 mL	17.2274 mL
5 mM	0.3445 mL	1.7227 mL	3.4455 mL
10 mM	0.1723 mL	0.8614 mL	1.7227 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (3.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.13%

Select Batch:

データシート (283 KB) SDS (396 KB)

COA (259 KB) HNMR (305 KB) RP-HPLC (269 KB) MS (68 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Slusarczyk M, et al. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J Med Chem. 2014 Feb 27;57(4):1531-42. [Content Brief]

細胞実験 ^[1]	NUC-1031(5.0 mg) is dissolved in DMSO (0.050 mL) and D₂O (0.15 mL). After recording the control ³¹P NMR at 37 °C, a previously defrosted human, rat, or dog serum (0.30 mL) is added to the sample, which is next submitted to the ³¹P NMR experiments at 37°C. The spectra are recorded every 30 min over 13 h. ³¹P NMR recorded data are processed and analyzed with the Bruker Topspin 2.1 program^[1]. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
動物実験 ^[1]	Balb/c nude mice are female, six to eight week old, with the weight of 20 ± 2 g. They are intraperitoneally given NUC-1031 (i.p 0.228 mmol/kg, 132.3 mg/kg, 2×/WK) or vehicle for 2 weeks. NUC-1031 is dissolved in 40% Captisol solution. (40% Captisol is prepared by dissolving 20mg of Captisol with pure water, and made the final volume 50 mL. The solvent is filtered with 0.22 μm filter). Mice are monitored daily for body weight change and clinical symptoms for 2 weeks^[1]. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
参考文献	[1]. Slusarczyk M, et al. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J Med Chem. 2014 Feb 27;57(4):1531-42. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7227 mL	8.6137 mL	17.2274 mL	43.0686 mL
	5 mM	0.3445 mL	1.7227 mL	3.4455 mL	8.6137 mL
	10 mM	0.1723 mL	0.8614 mL	1.7227 mL	4.3069 mL
	15 mM	0.1148 mL	0.5742 mL	1.1485 mL	2.8712 mL
	20 mM	0.0861 mL	0.4307 mL	0.8614 mL	2.1534 mL
	25 mM	0.0689 mL	0.3445 mL	0.6891 mL	1.7227 mL
	30 mM	0.0574 mL	0.2871 mL	0.5742 mL	1.4356 mL
	40 mM	0.0431 mL	0.2153 mL	0.4307 mL	1.0767 mL
	50 mM	0.0345 mL	0.1723 mL	0.3445 mL	0.8614 mL
	60 mM	0.0287 mL	0.1436 mL	0.2871 mL	0.7178 mL

Acelarin Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Acelarin840506-29-8NUC-1031NUC1031NUC 1031DNA/RNA SynthesisInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Acelarin (Synonyms: NUC-1031)

カスタマーレビュー

Other Forms of Acelarin:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Acelarin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Acelarin (Synonyms: NUC-1031)

カスタマーレビュー

Other Forms of Acelarin:

Acelarin 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Acelarin 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Acelarin Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report